NCT03164486View on ClinicalTrials.gov

First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Breast CarcinomaColorectal CarcinomaLung CarcinomaMetastatic Malignant Neoplasm in the BreastMetastatic Malignant Neoplasm in the ColonMetastatic Malignant Neoplasm in the LungMetastatic Malignant Neoplasm in the RectumPancreatic Carcinoma
Interventions
DRUG

18F-αvβ6-BP

Subjects will be injected once with up to 10 mCi of 18F-αvβ6-BP as a rapid intravenous bolus (within 30 seconds).

Trial Locations (1)

95817

University of California Davis Comprehensive Cancer Center, Sacramento

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Julie L. Sutcliffe, Ph.D

OTHER